Vurdering af immunogenicitet og klinisk virkning En sammenlignende undersøgelse af 1 279 personer, som fik M- M- RVAXPRO eller den tidligere formulering af mæslinge -, parotitis - og rubellavaccine (fremstillet med humant serumalbumin) fremstillet af Merck & Co., Inc. påviste ens immunogenicitet og sikkerhed af de 2 produkter.
Evaluation of immunogenicity and clinical efficacy A comparative study in 1279 subjects who received M-M-RVAXPRO or the previous formulation (manufactured with human serum albumin) of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. demonstrated similar immunogenicity and safety between the 2 products.